PUBLIC COMPANY
save280Bio Inc
South San Francisco, CA, USupdated 1mo ago
280Bio is a clinical-stage precision oncology biotech and a wholly owned subsidiary of Shanghai Yingli Pharmaceutical, developing orally available small-molecule inhibitors of RAS signaling and other frequently mutated cancer pathways. Its lead candidate TEB-17231 (also known as YL-17231) is a pan-RAS inhibitor in Phase 1 trials for advanced solid tumors harboring KRAS, HRAS, or NRAS mutations.
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
comments(0)
5-min edit window · permanent after that